StockData

IRulya Therapeutics Inc. (IRLA) company profile

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$38.45+1.09 (+2.92%)

Close on Nov 17, 2026Market cap $39.11MP/E –Yield –

About IRulya Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Quince Therapeutics, Inc. is a biotechnology company that historically focused on developing therapies for rare diseases by utilizing a patient's own red blood cells for drug delivery. The company's proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform consists of an automated drug and device combination designed to encapsulate drugs into autologous red blood cells to enhance biodistribution, extend half-life, and improve tolerability across small molecules and biologics. Its lead asset was eDSP, which encapsulated dexamethasone sodium phosphate for the treatment of ataxia-telangiectasia. Following disappointing results in its Phase 3 NEAT trial, the company discontinued further clinical development of eDSP and ceased research activities.

The company operates with no other active drug candidates and conducts its principal operations from South San Francisco, California. Having halted pipeline development, it focuses its present activities on cash preservation and the evaluation of potential strategic alternatives.

Summary of the business section of IRulya Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
IRulya Therapeutics Inc.
Founded
2012
Headquarters
New Haven, CT
Address
101 College Street, Suite 210 06510
Phone
(203) 208-8994
Employees
38, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Jose, California

Stock & identifiers

Ticker
IRLA
Former tickers
CRTX until Oct 19, 2026
Exchange
Nasdaq
IPO date
May 9, 2019
Shares outstanding
1M, Aug 7, 2026
Public float
$64.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Jun 30, 2026; 1-for-10 reverse, Apr 13, 2026
SEC CIK
1662774
CUSIP
22053A305
ISIN
US22053A3059
FIGI
BBG00BTK1DT8
Share class FIGI
BBG00BTK1DS9
EIN
90-1024039

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brigette RobertsChief Corp. Affairs Officer, Director–
Dirk ThyeCEO and CMO, Director994,885
John MilitelloChief Financial Officer80,000
Keith R. FandrickChief Operating Officer–
Brendan HannahCBO, COO & CCO336,547
Charles S. RyanPresident130,009
Catherine M. BonuccelliDirector–
Leone D. PattersonDirector–
John Drayton WiseDirector–
James Elwood ValentineDirector–
Christopher J. SennerDirector0
David LamondDirector6,974,754
Margaret McLoughlinDirector8,000
June BrayDirector–
Luca BenattiDirector39,179
Rajiv PatniDirector–
Una S. RyanDirector2,875

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.41M$3.94M$1.17M$526–
FY2024$2.73M$3.37M$1.13M$293–
FY2023
Casey C.Lynch
$0$0$1.00M$165–
FY2023
Christopher Lowe
$0$0$1.00M$165–
FY2023
Dirk Thye M.d.
$1.33M$2.49M$1.00M$165–
FY2022$5.17M-$1.87M$2.75M$5–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Dirk Thye
Chief Executive Officer and Chief Medical Officer
$550.00K$1.64M$295.63K$4.00K$2.49M-9%
Charles Ryan
President
$500.00K$411.00K$207.50K$25.60K$1.14M+28%
Brendan Hannah
Chief Operating Officer, Chief Business Officer and Chief Compliance Officer
$453.75K$616.50K$188.83K$4.00K$1.26M-8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 9, 2019
Offer price
$17.00
Securities offered
4,412,000
Gross proceeds
$75.00M
Exchange
Nasdaq
Lock-up ends (est.)
Nov 5, 2019

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 38 total employees, of which 25 are in research and development and 13 are in general and administrative.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?